AU2001288369A1 - Method of monitoring the effect of cathepsin s inhibitors - Google Patents

Method of monitoring the effect of cathepsin s inhibitors

Info

Publication number
AU2001288369A1
AU2001288369A1 AU2001288369A AU8836901A AU2001288369A1 AU 2001288369 A1 AU2001288369 A1 AU 2001288369A1 AU 2001288369 A AU2001288369 A AU 2001288369A AU 8836901 A AU8836901 A AU 8836901A AU 2001288369 A1 AU2001288369 A1 AU 2001288369A1
Authority
AU
Australia
Prior art keywords
cathepsin
inhibitors
monitoring
effect
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288369A
Other languages
English (en)
Inventor
Lars Karlsson
Siquan Sun
Robin Thurmond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of AU2001288369A1 publication Critical patent/AU2001288369A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125—Digestion or removing interfering materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
AU2001288369A 2000-09-06 2001-08-24 Method of monitoring the effect of cathepsin s inhibitors Abandoned AU2001288369A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23048400P 2000-09-06 2000-09-06
US60230484 2000-09-06
PCT/US2001/026373 WO2002021129A1 (fr) 2000-09-06 2001-08-24 Procede relatif au controle de l'effet d'inhibiteurs de cathepsine s

Publications (1)

Publication Number Publication Date
AU2001288369A1 true AU2001288369A1 (en) 2002-03-22

Family

ID=22865403

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288369A Abandoned AU2001288369A1 (en) 2000-09-06 2001-08-24 Method of monitoring the effect of cathepsin s inhibitors

Country Status (10)

Country Link
US (1) US7026132B2 (fr)
EP (1) EP1315966B1 (fr)
JP (1) JP2004508553A (fr)
AT (1) ATE374945T1 (fr)
AU (1) AU2001288369A1 (fr)
CA (1) CA2421558A1 (fr)
DE (1) DE60130784T2 (fr)
DK (1) DK1315966T3 (fr)
ES (1) ES2295206T3 (fr)
WO (1) WO2002021129A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6784288B2 (en) 2001-11-08 2004-08-31 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of monkey cathepsin S
US6780985B2 (en) 2001-11-08 2004-08-24 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of Canine Cathepsin S
WO2006125105A2 (fr) * 2005-05-19 2006-11-23 Wyeth Methodes et compositions de traitement et de diagnostic d'une sclerose en plaques
EP2436776A1 (fr) 2010-10-01 2012-04-04 F. Hoffmann-La Roche AG Procédé pour la surveillance de l'inhibition de la cathepsine S
EP3194610B1 (fr) * 2014-09-18 2019-11-13 F.Hoffmann-La Roche Ag Anticorps anti li p10

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
WO1997010335A1 (fr) * 1995-09-14 1997-03-20 Universität Tübingen Polypeptide recombine contenant la sequence primaire de la chaine invariante avec au moins une sequence primaire d'un epitope de cellule t specifique ou d'un derive proteique et acides nucleiques codant ledit polypeptide recombine
DK0912601T4 (da) 1996-04-22 2009-03-09 Massachusetts Inst Technology Suppression af immunrespons ved inhibering af cathepsin S
AU3307497A (en) * 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
WO1999058153A1 (fr) * 1998-05-08 1999-11-18 Brigham & Women's Hospital Procedes de diagnostic et de modulation de l'auto-immunite
US6495333B1 (en) * 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay

Also Published As

Publication number Publication date
EP1315966A4 (fr) 2005-07-27
EP1315966B1 (fr) 2007-10-03
DE60130784D1 (de) 2007-11-15
EP1315966A1 (fr) 2003-06-04
WO2002021129A1 (fr) 2002-03-14
JP2004508553A (ja) 2004-03-18
US7026132B2 (en) 2006-04-11
CA2421558A1 (fr) 2002-03-14
DK1315966T3 (da) 2008-01-02
ATE374945T1 (de) 2007-10-15
US20020028435A1 (en) 2002-03-07
ES2295206T3 (es) 2008-04-16
DE60130784T2 (de) 2008-07-17

Similar Documents

Publication Publication Date Title
GB2367594B (en) Calibration of pumps, such as blood pumps of dialysis machines
AU2002309757A1 (en) Process and system for prescribing, administering and monitoring a treatment regimen for a patent
PT1258476E (pt) Derivados de alfa-amino-acidos, processo para sua preparacao assim como a sua utilizacao como inibidores de dipeptidil-peptidase iv (dpp iv).
DE60208448D1 (de) Manschette für Blutdrucküberwachung
EA200000814A1 (ru) Фармацевтическая композиция топирамата
WO2002096363A3 (fr) Methode de traitement de maladies fibreuses ou d'autres indications
WO2007079146A8 (fr) Traitement pour un lymphome non hodgkinien
AU2002366787A1 (en) Blood pressure measuring apparatus
WO2004037789A3 (fr) Derives de methylene uree
AU2002352531A1 (en) Use of at least one glycoinhibitor substance
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
ITMI20031343A1 (it) Confezione plurima, e macchina e metodo per la sua fabbricazione.
AU2001288369A1 (en) Method of monitoring the effect of cathepsin s inhibitors
AU2001247863A1 (en) Method for systolic blood pressure measurement
IL173850A0 (en) Method for the in vitro titration of an ncta and application thereof in a method for the evaluation and/or monitoring of a biological product production method
AU2002250613A1 (en) Microsensor for physiological pressure measurement
EP1591130A3 (fr) Utilisation d'une composition active pour la désinfection et/ou stérilisation d'une unité dentaire
WO2007067912A8 (fr) Traitement et diagnostic de maladies inflammatoires
MY141756A (en) Use of phenoxyacetic acid derivatives for treating hyperactive bladder
WO2002069987A3 (fr) Agent pour traiter le diabete sucre
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
IL156639A0 (en) Phenethanolamine derivatives, methods for their preparation and pharmaceutical compositions containing them
SE0202608D0 (sv) New sequences
WO2002036069A3 (fr) Hypotension
WO2000023058A3 (fr) Methode de traitement